source
- Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trialTyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…
- Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic diseaseCaspian Therapeutics, a spin‑out from Kura Oncology, announced it is starting operations with $50 million in financing. The capital, led by BVF Partners and joined by Eli Lilly and Kura leadership,…